John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...

A Bluebird Bio gene therapy has helped children with a devastating neurological disorder, but seven have developed blood ...

Researchers will develop therapies for urea cycle disorders and create a platform to rapidly develop treatments for other rare genetic disorders.

A new technology enables the control of specific brain circuits non-invasively with magnetic fields, according to a ...

A new gene drive can copy and paste itself into the genomes of herpes simplex viruses in mice. The end goal is a version that disables the virus in humans.

Since the FDA cleared Sarepta Thereapeutics' gene therapy for nearly all people with Duchenne, its stock price has tanked.

Purespring raises £80 million in a Series B financing, with Syncona committing £19.9 million[1] as part of a leading syndicate of life science investorsProceeds will be used to advance Purespring’s ...

Our round-up of recent biotech financings features a strong first round for City Therapeutics, a new RNAi venture led by ...

Purespring Therapeutics Ltd. has raised £80 million (US$104.6 million) in a series B, putting it on course to be the first to ...

Biotechnology company Purespring Therapeutics has raised about $105 million to fund its development of gene therapies for ...

Purespring Therapeutics, a UK-based gene therapy company focused on kidney disease, has raised £80 million ($105 million) in ...

The London-based firm said it will use the funds to advance its gene therapy pipeline, including its lead program in IgA nephropathy.